arrow
S

Selina Chen-Kiang

harvard university medical affiliates
H指数:56
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma

微小残留病驱动的阿卡替尼联合来那度胺与利妥昔单抗(ALR)或奥比妥珠单抗(ALO)初始治疗套细胞淋巴瘤

2025-11-270
OAAI
MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naive Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

MRD驱动的有限疗程Acalabrutinib联合Lenalidomide和Rituximab(ALR)或Obinutuzumab(ALO)治疗初治套细胞淋巴瘤患者的疗效:含MRD和cfDNA分析的II期试验结果

BLOOD
IF23.1
2024-11-051
PRE
CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

CDK4/6抑制通过同时破坏MEIS2-CRBN的关联以及对抗调节MEIS2和CRBN的合成,逆转了MEIS2对CRL4CRBN的抑制,从而增强IMiD疗法在多发性骨髓瘤中的效果。

BLOOD
IF23.1
2024-11-050
PRE
Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

干扰IL10信号克服了复合拷贝数变异驱动的临床耐药性,对CDK4/6和BTK抑制在套细胞淋巴瘤中的作用

BLOOD
IF23.1
2024-11-050
PRE
Resistance to PRMT5-targeted therapy in mantle cell lymphoma
2023-12-292
OAAI
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
2023-10-133
OAAI
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation
2023-01-0615
OAAI
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas
2022-12-158
OAAI
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
2022-07-139
OAAI
Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma
2018-05-1466
OAAI